Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem - PubMed (original) (raw)

Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem

William H Polonsky et al. Diabetes Care. 2005 Oct.

No abstract available

PubMed Disclaimer

Similar articles

• Factors associated with psychological insulin resistance in individuals with type 2 diabetes.
  Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Nam S, et al. Diabetes Care. 2010 Aug;33(8):1747-9. doi: 10.2337/dc10-0099. Epub 2010 Apr 30. Diabetes Care. 2010. PMID: 20435797 Free PMC article.
• Psychological insulin resistance: overcoming barriers to starting insulin therapy.
  Davis SN, Renda SM. Davis SN, et al. Diabetes Educ. 2006 Jun;32 Suppl 4:146S-152S. doi: 10.1177/014572170603204s01. Diabetes Educ. 2006. PMID: 16831818 No abstract available.
• NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance.
  Hunt LM, Valenzuela MA, Pugh JA. Hunt LM, et al. Diabetes Care. 1997 Mar;20(3):292-8. doi: 10.2337/diacare.20.3.292. Diabetes Care. 1997. PMID: 9051375
• The use of insulin to improve treatment in type 2 diabetes.
  Hill J. Hill J. Nurs Times. 2005 Jul 12-18;101(28):32-4. Nurs Times. 2005. PMID: 16047998 Review.
• Psychological insulin resistance: patient beliefs and implications for diabetes management.
  Brod M, Kongsø JH, Lessard S, Christensen TL. Brod M, et al. Qual Life Res. 2009 Feb;18(1):23-32. doi: 10.1007/s11136-008-9419-1. Epub 2008 Nov 28. Qual Life Res. 2009. PMID: 19039679 Review.

Cited by

• Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.
  Golden SH, Brown A, Cauley JA, Chin MH, Gary-Webb TL, Kim C, Sosa JA, Sumner AE, Anton B. Golden SH, et al. J Clin Endocrinol Metab. 2012 Sep;97(9):E1579-639. doi: 10.1210/jc.2012-2043. Epub 2012 Jun 22. J Clin Endocrinol Metab. 2012. PMID: 22730516 Free PMC article.
• Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.
  Brod M, Valensi P, Shaban JA, Bushnell DM, Christensen TL. Brod M, et al. Qual Life Res. 2010 Nov;19(9):1285-93. doi: 10.1007/s11136-010-9699-0. Epub 2010 Jul 4. Qual Life Res. 2010. PMID: 20602172 Free PMC article.
• Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: the inhaled insulin treatment questionnaire (IITQ).
  Rubin RR, Peyrot M. Rubin RR, et al. Health Qual Life Outcomes. 2010 Mar 24;8:32. doi: 10.1186/1477-7525-8-32. Health Qual Life Outcomes. 2010. PMID: 20334647 Free PMC article. Clinical Trial.
• Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence.
  Moore DJ, Gregory JM, Kumah-Crystal YA, Simmons JH. Moore DJ, et al. Vasc Health Risk Manag. 2009;5:1015-31. doi: 10.2147/vhrm.s4891. Epub 2009 Nov 23. Vasc Health Risk Manag. 2009. PMID: 19997571 Free PMC article. Review.
• Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
  Dailey G, Admane K, Mercier F, Owens D. Dailey G, et al. Diabetes Technol Ther. 2010 Dec;12(12):1019-27. doi: 10.1089/dia.2010.0063. Diabetes Technol Ther. 2010. PMID: 21128849 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information